Intensity Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 17
- Market Cap
- $59.2M
- Introduction
Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
- Conditions
- Sarcoma,Soft Tissue
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT06263231
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of California Los Angeles (UCLA) - Santa Monica Cancer Care, Santa Monica, California, United States
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
- Conditions
- LymphomaLiver CancerColon CancerHead and Neck CancerLung CancerChordoma of SacrumBreast CancerSquamous Cell CarcinomaBile Duct CancerSarcoma
- Interventions
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT03058289
- Locations
- 🇺🇸
USC Norris, Los Angeles, California, United States
🇺🇸USC HOAG, Newport Beach, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
News
Intensity Therapeutics Secures $2.35 Million in Public Offering to Advance Cancer Immunotherapy Trials
Intensity Therapeutics has priced a $2.35 million public offering to fund ongoing clinical trials of its novel intratumoral cancer therapy INT230-6, which has shown promise in killing tumors and triggering immune responses.
Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development
Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.
Intensity Therapeutics' Sarcoma Trial INT230-6 Authorized to Continue by DMC
Intensity Therapeutics' Phase 3 INVINCIBLE-3 study of INT230-6 in soft tissue sarcoma is authorized to continue without modifications after a Data Monitoring Committee review.
Intensity Therapeutics' INT230-6 Shows Promise in Localized Cancer Reduction and Systemic Immune Activation
Intensity Therapeutics is pioneering localized cancer reduction with INT230-6, designed to kill tumors and stimulate the immune system.
Intensity Therapeutics Secures $3 Million to Advance Cancer Therapies
Intensity Therapeutics has secured $3 million through a direct stock offering and private placement to bolster its working capital.
Windtree and Intensity Therapeutics Report Progress in Heart Failure and Oncology
Windtree Therapeutics reported positive Phase 2b results for istaroxime in early cardiogenic shock, showing significant improvements in cardiac function and blood pressure.
Intensity Therapeutics and Fractyl Health Advance Clinical Programs in Oncology and Metabolic Disease
Intensity Therapeutics doses first patient in Phase 2 trial for triple-negative breast cancer and progresses Phase 3 sarcoma study.
Intensity Therapeutics and SAKK Initiate Phase 2 Trial of INT230-6 in Triple-Negative Breast Cancer
Intensity Therapeutics and SAKK collaborate on INVINCIBLE-4, a Phase 2 trial evaluating INT230-6 plus standard-of-care (SOC) versus SOC alone in localized triple-negative breast cancer (TNBC).
Intensity Therapeutics Initiates Phase 3 Trial of INT230-6 for Metastatic Sarcoma
Intensity Therapeutics has dosed the first US patient in its global Phase 3 INVINCIBLE-3 trial testing INT230-6 as monotherapy for metastatic soft tissue sarcoma.